Last edition
News about "GSK India"
GSK India Reports 24 Percent PAT Growth in Q1 FY27
GSK India reported 15 percent revenue growth to INR 924 crore and a 24 percent rise in Q1 FY27 PAT to INR 253 crore, with EBITDA margin of 32 percent.
GSK India | 04/08/2026 | By News Bureau
GSK Enters Oncology in India with Launch of Jemperli and Zejula for Gynaecological Cancers
GSK has launched its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.
GSK India | 25/08/2025 | By Dineshwori | 376
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy